{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:14:27Z","timestamp":1777601667195,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Etoposide phosphate (EP; single injection, 60\u00a0mg\/kg) followed by total body irradiation (TBI) at 12 Gy has been used as an allogeneic stem cell transplantation (allo\u2010SCT) conditioning regimen for children since 2010. In our institution, EP has been suspected of leading to acute nephrotoxicity. The aim of this study was to assess the potential renal toxicity of EP in this context.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective study was carried out on children hospitalized between 2007 and 2015 for allo\u2010SCT with TBI\u2010based myeloablative conditioning associated with cyclophosphamide (CY, 60\u00a0mg\/kg\/day\u00a0\u00d7\u00a02 days) or EP. The primary endpoint of the study was the occurrence of acute kidney injury (AKI). Additional endpoints were time to recovery for children with AKI, survival, and treatment\u2010related mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010five patients were analyzed (CY: 22 vs. EP: 13). AKI occurred more frequently in the EP group than in the CY one (69% vs. 27%, adjusted odds ratio 6.0, 95% confidence interval [CI] [1.145; 31.445], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.03). The median time to recovery was estimated at 3 days, 95% CI (2; 17), with CY and 11 days 95% CI (5; 18) with EP (adjusted hazard ratio of recovery for EP vs. CY 0.262, 95% CI [0.071; 0.969], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.04). No significant difference was highlighted between the two treatments for survival or for treatment\u2010related mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study shows that EP at high dosage or one of its excipients is probably responsible for AKI, as compared to CY. Further studies are required to explore the origin of this adverse effect.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.27038","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T10:46:42Z","timestamp":1520851602000},"source":"Crossref","is-referenced-by-count":14,"title":["Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation"],"prefix":"10.1002","volume":"65","author":[{"given":"Delphine","family":"Barnoud","sequence":"first","affiliation":[{"name":"CHU Lille Institut de Pharmacie  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Pin\u00e7on","sequence":"additional","affiliation":[{"name":"EA 2694\u2014Sant\u00e9 publique: \u00e9pid\u00e9miologie et qualit\u00e9 des soins Universit\u00e9 de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Bruno","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie P\u00e9diatrique Centre Hospitalier Regional Universitaire de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Centre Hospitalier Regional Universitaire de Lille  Lille France"},{"name":"U1171\u2014Degenerative &amp; Vascular Cognitive Disorders Universit\u00e9 de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Centre Hospitalier Regional Universitaire de Lille  Lille France"},{"name":"U1171\u2014Degenerative &amp; Vascular Cognitive Disorders Universit\u00e9 de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Lahoche","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie P\u00e9diatrique Centre Hospitalier Regional Universitaire de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[{"name":"Laboratoire de pharmacologie clinique et toxicologie centre r\u00e9gional de pharmacovigilance de Lorraine h\u00f4pital Central Centre Hospitalier Regional Universitaire de Nancy  Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Vasseur","sequence":"additional","affiliation":[{"name":"CHU Lille Institut de Pharmacie  F\u201059000 Lille France"},{"name":"Univ. Lille EA 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[{"name":"Univ. Lille EA 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"D\u00e9caudin","sequence":"additional","affiliation":[{"name":"CHU Lille Institut de Pharmacie  F\u201059000 Lille France"},{"name":"Univ. Lille EA 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-440X","authenticated-orcid":false,"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[{"name":"CHU Lille Institut de Pharmacie  F\u201059000 Lille France"},{"name":"Univ. Lille EA 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Odou","sequence":"additional","affiliation":[{"name":"CHU Lille Institut de Pharmacie  F\u201059000 Lille France"},{"name":"Univ. Lille EA 7365 \u2013 GRITA \u2013 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es  F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2013.01.021"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.12.029"},{"key":"e_1_2_8_4_1","unstructured":"ALL SCTped 2012 FORUM.Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia International Therapy Protocol.2014."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00684867"},{"key":"e_1_2_8_6_1","unstructured":"Medicines and healthcare products regulatory agency.Etoposide\u2014Eposin\u00ae Summary of product characteristics.http:\/\/www.mhra.gov.uk.2018."},{"key":"e_1_2_8_7_1","first-page":"108","article-title":"Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids","volume":"45","author":"Beijnen JH","year":"1991","journal-title":"J Parenter Sci Technol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26669"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.328"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002231"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0952"},{"key":"e_1_2_8_14_1","first-page":"229","volume-title":"N\u00e9phrologie et Troubles Hydro\u2010\u00e9lectriques","author":"Kanfer A","year":"2014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00301.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181cd12e1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02408.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10535-9"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1404711"},{"key":"e_1_2_8_20_1","volume-title":"Handbook of Pharmaceutical Excipients","author":"Rowe RC","year":"2012"},{"key":"e_1_2_8_21_1","volume-title":"Martindale, The Complete Drug Reference","author":"Sweetman RC","year":"2011"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-4-500"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/08860229709026293"},{"key":"e_1_2_8_24_1","unstructured":"Medicines and healthcare products regulatory agency. Dextran\u2014RescueFlow\u00ae Summary of product characteristics.http:\/\/www.mhra.gov.uk.2018."},{"key":"e_1_2_8_25_1","first-page":"331","article-title":"A 16\u2010month survey of cyclosporine utilization evaluation in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Ardakani AT","year":"2016","journal-title":"Int J Pharmaceut Res"},{"key":"e_1_2_8_26_1","first-page":"164","article-title":"Nephrotoxicity of anti\u2010infective drugs","volume":"36","author":"Schwartz A","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/980301"},{"key":"e_1_2_8_28_1","first-page":"18","article-title":"Stability of high\u2010dose etoposide dilutions for use in hematopoietic stem cell transplantation conditioning regimens","volume":"95","author":"Bauters T","year":"2015","journal-title":"J Pharm Belg"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:51:47Z","timestamp":1695513107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/pbc.27038"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27038","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"article-number":"e27038"}}